Fever

iHealth Unveils Breakthrough 3-in-1 At-Home 15-Minute Antigen Test for COVID-19 and Flu A&B

Retrieved on: 
Mittwoch, Mai 8, 2024
FDA, Physician, Public, National library, COVID, Safety, Food, Uncertainty, Health, Emergency Use Authorization, Parent, Cough, Federation, Family, Fatigue, Face, Virus, Sneeze, Infection, Child, Fever, COVID-19, Ageing, Pharmaceutical industry

With the launch of the 3-in-1 COVID-19/Flu A&B Rapid Test, iHealth, one of the leading suppliers of at-home COVID tests to the federal government, ushers in a new era of at-home testing post-pandemic that will enable consumers to stop guessing what illness they may have when symptoms emerge. According to infectious disease physicians, it's important to know if you have COVID or the flu as they have different treatments--although they have similar symptoms. 

Key Points: 
  • As one of the first over-the-counter rapid antigen tests for COVID-19 and influenza (commonly known as the flu) A & B in the US, the 3-in-1 test offers a convenient and fast at-home testing experience.
  • The 3-in-1 test inherits the same user-friendly steps of iHealth's stand-alone at-home COVID test.
  • The difference lies in squeezing 5 drops onto a test card, compared to the previous 3 drops.
  • For more information on the iHealth COVID-19/Flu A&B 3-in-1 Antigen Rapid Test, visit the product page on the www.ihealthlabs.com website.

Project Lyme Harnesses the Power of Public Service Announcements to Inform Parents Their Child's Complex Illness Could Be Lyme

Retrieved on: 
Mittwoch, Mai 8, 2024
Myalgia, Risk, CDC, Health, Arthralgia, DSM-IV codes, Parent, Depression, Conditional sentence, Tic disorder, Pressure, Patient, Lyme disease, Headache, Fatigue, Irritability, Lymph, Multimedia, Diagnosis, Infection, Fever, Anxiety, Approximation error, PSAS, Tick-borne disease, Deficit spending, Heart failure, Pharmaceutical industry

NEW YORK, May 8, 2024 /PRNewswire/ -- The CDC now estimates nearly half a million people will contract Lyme disease in the United States each year. However, most people do not realize how Lyme disease can cause diverse, devastating symptoms in some patients. The range of symptoms is expansive and often overwhelming, from flu-like symptoms such as fatigue, fever, enlarged lymph nodes, headaches, muscle aches, and joint pain in the early stages to more serious issues such as cognitive impairment, sleep problems, mood changes, shortness of breath or heart failure when a diagnosis is missed or delayed. Lyme has been reported in all 50 states, with case counts increasing throughout the country. As the risk of contracting a tick-borne infection increases nationally, it is imperative to educate a broader audience, especially parents of young children.

Key Points: 
  • However, most people do not realize how Lyme disease can cause diverse, devastating symptoms in some patients.
  • Children are at the greatest risk of contracting Lyme disease and delayed diagnosis can prevent them from living a normal life.
  • In their new PSAs , Project Lyme tells the stories of Rylyn and Pippa , two young children who are recovering from Lyme disease.
  • Project Lyme's PSAs provide advice that if you are unsure of the source of your child's illness, it could be Lyme.

StubHub's Inaugural WNBA Season Preview: Caitlin Clark Fuels Surge in Demand for the Entire League, Alongside Other Former NCAAW Players in Their Rookie Years

Retrieved on: 
Mittwoch, Mai 1, 2024
Fever, Liberty, WNBA Finals, StubHub, WNBA, Las Vegas Aces, Ace, Top, Growth, Indiana Fever, Vaccine

NEW YORK, May 1, 2024 /PRNewswire/ -- As we gear up for the highly anticipated 2024 WNBA season, StubHub has launched its inaugural WNBA Season Preview, revealing the top-selling teams, games, and trends of the season. This year marks another pivotal moment for women's sports, with WNBA sales on StubHub growing by 93% compared to last season. The Indiana Fever is at the forefront of this growth, with sales skyrocketing 13-fold, following their draft pick of college basketball star Caitlin Clark.

Key Points: 
  • This year marks another pivotal moment for women's sports, with WNBA sales on StubHub growing by 93% compared to last season.
  • The Indiana Fever is at the forefront of this growth, with sales skyrocketing 13-fold, following their draft pick of college basketball star Caitlin Clark.
  • "The 2023 WNBA Finals set a record for the league on StubHub, with sales tripling compared to the previous year.
  • Now, as we head into this season, Caitlin Clark's impact is electrifying, sparking an unprecedented 15x increase in searches for the Indiana Fever after her WNBA draft announcement."

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Retrieved on: 
Dienstag, April 30, 2024
Pain, FDA, Omeprazole, Fungal infection, Gastroenterology, Lactulose, PIN, Skin, Clarithromycin, Nausea, Hyponatremia, Infection, Paracetamol, Amoxicillin, Cardiomyopathy, Duchenne muscular dystrophy, Helicobacter pylori, Vomiting, Patient, Idiopathic pulmonary fibrosis, Constipation, Granisetron, Multimedia, Health, Acetylcysteine, Fever, Ibuprofen

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
  • A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.

Fujifilm and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of Biopharmaceuticals

Retrieved on: 
Donnerstag, April 25, 2024
FDA, USP, Inflammation, Bacteria, Death, LPS, Lipopolysaccharide, Patient, LAL, Limulus amebocyte lysate, Gram-negative bacteria, Fujifilm, Fever

Corporation (Fujifilm), a supplier of high purity chemicals and reagents, and Predictive Oncology Inc., (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that the companies have entered into a collaboration and co-marketing agreement to reduce protein interference in bacterial endotoxin testing of biopharmaceutical products.

Key Points: 
  • Corporation (Fujifilm), a supplier of high purity chemicals and reagents, and Predictive Oncology Inc., (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that the companies have entered into a collaboration and co-marketing agreement to reduce protein interference in bacterial endotoxin testing of biopharmaceutical products.
  • Per the terms of the agreement, Predictive Oncology will utilize its novel EndoPrep™ sample treatment technology (EndoPrep), together with Fujifilm’s PYROSTAR™ bacterial endotoxin detection reagent (PYROSTAR), to detect residual endotoxins more accurately in biopharmaceuticals by eliminating protein interference from the drug product in the detection assay.
  • The Limulus Amebocyte Lysate (LAL) test is recognized by the U.S. Pharmacopeia (USP) for determining endotoxin levels in many biopharmaceuticals.
  • *Compared to traditional industry standards of utilizing heat-treatment or dilution to remove the interference of high protein.

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Retrieved on: 
Dienstag, April 23, 2024
Neuro-Oncology (journal), First grade, FDA, Society, University, BRAF V600, Day One, Hospital, Acne, Safety, Food, Biopharmaceutical, Conference call, Nausea, Insurance, Conference, Research, Webcast, Viral, Speech, Fatigue, Human, Disease, BRAF, Vomiting, Patient, Medicine, Headache, Event, Rash, Constipation, Diagnosis, Head, Neoplasm, Upper respiratory tract infection, PRS, Xeroderma, Fever, Caregiver, Ageing, Pharmaceutical industry

BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.

Key Points: 
  • With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.
  • “We are very proud that our first approved medicine addresses this serious and life-threatening disease of childhood and adolescence.
  • BRAF is the most commonly altered gene in pLGG, with up to 75 percent of children having a BRAF alteration.
  • “This is a tremendous moment not only for Day One, but also for the broader pediatric brain tumor community.

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

Retrieved on: 
Dienstag, April 23, 2024
RVV, FDA, COVID, Safety, Economics, CDC, Infection, Death, Trial of the century, Doctor of Philosophy, Research, Cough, Heart rate, Therapy, Patient, Hospital, Fever, COVID-19, Harvard University, Pharmaceutical industry

The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1.

Key Points: 
  • The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1.
  • Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID.
  • The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA.
  • Additional analyses of the Study data may suggest Bucillamine’s potential for long COVID.

Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement

Retrieved on: 
Montag, April 15, 2024
Sale, Brain, Pain, Myalgia, Stroke, Woman, Tissue, Dietary supplement, Infertility, Infection, Testosterone, DSM-IV codes, Pelvic floor dysfunction, Male, Climacteric, Insomnia, System, Dementia, Dysmenorrhea, Erectile dysfunction, Lipid, Anxiety, Toothache, Oxygen, Headache, Acquisition, Memory, Libido, Tribulus terrestris, Tracheobronchitis, Fever, Metamizole

HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.

Key Points: 
  • HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.
  • The acquisition includes full dossiers for each product, which will allow NKPH to quickly register them for sale once the company has finalized the branding of each.
  • The technologies, which were purchased through NKPH’s subsidiary, Nika Europe Ltd., have a proven market track record, as each of them satisfy an important health need of the population.
  • MENTHYL VALERATE 60mg is an over-the-counter drug with a positive effect on the central nervous and cardiovascular systems.

Nine-year-old Southern California Leukemia Survivor Will Meet Donor Who Saved Her Life at City of Hope’s Bone Marrow Transplant Reunion

Retrieved on: 
Dienstag, April 30, 2024
Oncology, Philanthropy, Health, Hospitals, Foundation, Research, Science, BMT, Bone marrow, Cancer, Patient, Multiple myeloma, Chronic myelomonocytic leukemia, City, Blood, Parent, Leukemia, Medicine, Life, Female, B cell, Lymphoma, Family, Transplant, Child, HIV, CIM, Fever, Longevity, Wang, Dentistry

On Friday, May 3, at a 10 a.m. press conference on the cancer center’s Duarte, California, campus, Tammy and her family will meet her donor for the first time at City of Hope’s 48th Annual Bone Marrow Transplant (BMT) Reunion.

Key Points: 
  • On Friday, May 3, at a 10 a.m. press conference on the cancer center’s Duarte, California, campus, Tammy and her family will meet her donor for the first time at City of Hope’s 48th Annual Bone Marrow Transplant (BMT) Reunion.
  • Early support from its philanthropic partners helped City of Hope become a leader and pioneer with bone marrow transplant and have ensured the program’s longevity and success.
  • City of Hope has exceptional survivor rates year after year, according to the Center for International Blood and Marrow Transplant Research.
  • In addition to Tammy and her family meeting her donor, Southern California resident Terry Greene, 71, who survived chronic myelomonocytic leukemia, will also meet his international donor, a 24-year-old college student.

Rising Malaria Threat: International SOS Shares Advice on How to Keep Your Workforce Healthy

Retrieved on: 
Dienstag, April 23, 2024
Technology, Mobile, Wireless, Other Travel, Health, Human Resources, Travel, Other Transport, Other Health, Consulting, Banking, Professional Services, Transport, Other Technology, Data Management, Education, Climate change, RTS, International, WHO, Diagnosis, World Health Organization, Risk, Insecticide, Parasitism, Death, Entomology, Life, Occupational medicine, NGO, Global Health, International SOS, Data management, Workforce, Non-governmental organization, Private sector, Mining, Fever, Infection, Vaccine

International SOS global assistance data reports a 15% increase in malaria-related assistance requests in 2023 compared to 2022.

Key Points: 
  • International SOS global assistance data reports a 15% increase in malaria-related assistance requests in 2023 compared to 2022.
  • It is predicted with climate change that this risk could grow, and malaria transmission could spread into countries previously free of malaria.
  • International SOS also provides consulting services for every part of a company’s malaria risk mitigation programme.
  • Join International SOS webinar ‘Climate Change and Malaria: Navigating the Global Health Landscape’ on 7 May, where our experts will discuss the relationship between climate change and malaria.